Intercept Pharmaceuticals closes $30M Series C financing

Friday, August 10, 2012 03:15 PM

Intercept Pharmaceuticals, a New York-based clinical stage biopharmaceutical company focused on chronic liver diseases, has completed a $30 million Series C preferred stock financing led by OrbiMed Advisors, a global healthcare investment firm, with existing majority investor Genextra of Italy also participating.

"This financing allows us to continue advancing our lead compound OCA in POISE, our phase III PBC [primary biliary cirrhosis] trial, while pursuing other therapeutic indications of interest," said Mark Pruzanski, MD, president and CEO of Intercept.

Intercept aims to enroll 180 patients who first enter a one year double-blind placebo-controlled pivotal trial phase, followed by an open label long-term safety extension phase for another five years. The primary endpoint of the pivotal phase is the achievement of an alkaline phosphatase (ALP) level of less than 1.67 times upper limit normal  (with at least a 15% reduction in ALP), together with a normal bilirubin level. Patients who attain these ALP and bilirubin thresholds have been shown in long-term studies to be at significantly lower risk of progressing to liver transplant and death.

In conjunction with the financing, OrbiMed's Jonathan Silverstein and Klaus Veitinger have joined Intercept's board of directors.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs